A 52-year-old man with dilated cardiomyopathy (ejection fraction 25%) and NYHA Class III heart failure is admitted with recurrent episodes of non-sustained ventricular tachycardia (NSVT) on 24-hour Holter monitoring. He is on optimal medical therapy (ACE inhibitor, beta-blocker, aldosterone antagonist). His electrolytes and renal function are normal. What is the most appropriate next step in management?

Explanation

## Clinical Context: NSVT in Dilated Cardiomyopathy This patient has: - **Severely reduced ejection fraction (EF 25%)** — high risk for sudden cardiac death (SCD) - **NSVT on Holter** — marker of electrical instability - **Dilated cardiomyopathy** — structural substrate for re-entrant VT - **Optimal medical therapy** — already on guideline-directed medical therapy (GDMT) ## Risk Stratification for SCD | Feature | Risk Level | Implication | |---------|-----------|-------------| | EF ≤35% + NSVT | **High** | ICD indicated | | EF ≤35% + inducible VT on EP study | **High** | ICD indicated | | EF 26–35% on GDMT | Intermediate | Consider ICD | | EF >35% + NSVT | Low | Medical therapy | ## Management Algorithm for NSVT in Cardiomyopathy ```mermaid flowchart TD A[NSVT on Holter]:::outcome --> B{EF ≤35%?}:::decision B -->|Yes| C{On GDMT?}:::decision B -->|No| D[Medical therapy + follow-up]:::action C -->|Yes| E[ICD Evaluation]:::action C -->|No| F[Optimize GDMT first]:::action E --> G[ICD implantation if EF remains ≤35%]:::action F --> H[Recheck EF in 3 months]:::action H --> I{EF improved?}:::decision I -->|No| E I -->|Yes| D ``` ## Key Point: **ICD is indicated for primary prevention of SCD in patients with EF ≤35% and NSVT on Holter, provided they are on optimal GDMT.** This is a Class IIa recommendation in major guidelines. ## High-Yield Facts: - **NSVT + EF ≤35% = ICD candidate**, not antiarrhythmic drug candidate - Antiarrhythmic drugs (amiodarone, sotalol) do NOT reduce mortality in cardiomyopathy and may increase risk (proarrhythmia) - ICD is the only therapy proven to reduce SCD mortality in this population [MADIT II, SCD-HeFT] - Amiodarone is reserved for VT storm or bridge therapy before ICD, NOT first-line ## Clinical Pearl: **"In cardiomyopathy with NSVT, think ICD, not drugs."** Antiarrhythmic drugs suppress ectopy but do not prevent fatal arrhythmias. Only ICD and cardiac resynchronization (if QRS >120 ms) improve survival. ## Why Each Option Is Wrong: ### Option A (Amiodarone): - Amiodarone does NOT reduce mortality in cardiomyopathy with NSVT - Increases risk of proarrhythmia and toxicity (thyroid, liver, lung) - Reserved for symptomatic VT or as bridge to ICD, not primary therapy ### Option C (Increase beta-blocker): - Beta-blockers are essential but insufficient for NSVT + EF ≤35% - Delaying ICD evaluation exposes patient to sudden death risk - Waiting 3 months is inappropriate for high-risk stratification ### Option D (Sotalol): - Sotalol has proarrhythmic potential in cardiomyopathy (torsades de pointes risk) - Does NOT reduce mortality in dilated cardiomyopathy - Contraindicated if QTc prolongation or renal impairment develops [cite:Harrison 21e Ch 297]